"Principle Test" for Isolation and Characterization of Circulating Cancer Cells (CTC)-CXCR4+.

Condition(s) studied

Investigational drug(s) / intervention(s)

CLG: The development of an innovative device (CLG) consisting of an aqueous gel based on hyaluronic acid and commercially available (Belotero) able to be loaded and to release chemokine CXCL12 recreating a kind of "fake niche" able to attract immune cells- and CTCs-CXCR4+. The added value is the ability to attract and trap cells capable of leaking out and potentially with a higher metastatic capacity.

Study summary

This is multicentric, interventional, non farmacological and prospective study.

Eligibility

Primary outcome measure(s)

• In vitro isolation of CTCs. — 2 years
  In vitro isolation of CTCs with high metastatic capacity from peripheral blood through CLG.Gene expression analysis will be performed using 250ng RNA for nCounter FLEX Analysis System (NanoStringTechnologies). Panels analyzed include the PanCancer Pathways and the PanCancer Progression. The data will be analyzed using the nSolver analysis software version 3.0
• Real-Time PCR to evaluate the expression of Epithelium-Mesenchymal Markers — 2 years
  Expression analysis of Epithelium-Mesenchymal Markers (EPCAM, SNAIL, VIMENTIN, N-CADERIN, E-CADERIN) will be performed using Real-Time PCR.

Trial sites (2)

More National Cancer Institute, Naples trials in Italy

Other trials for the same condition